Volume 22, Number 4—April 2016
CME ACTIVITY - Research
Shiga Toxin 1–Producing Shigella sonnei Infections, California, United States, 2014–2015
Table 1
Characteristic | Value |
---|---|
Symptoms | |
Diarrhea | 56/56 (100.0) |
Abdominal cramps | 45/52 (86.5) |
Fever† | 36/50 (72.0) |
Bloody diarrhea | 36/51 (70.6) |
Chills | 26/41 (63.4) |
Nausea | 22/39 (56.4) |
Vomiting | 21/48 (43.8) |
Headache |
10/33 (30.3) |
Outcomes | |
Emergency department visit | 27/51 (52.9) |
Hospitalization | 12/56 (21.4) |
Hemolytic uremic syndrome | 0/43 |
Death | 0/56 |
Median duration of symptoms, d (IQR) | 5 (3–7)‡ |
Median length of hospitalization, d (IQR) |
3 (1.5–4)§ |
Antimicrobial resistance | |
Trimethoprim/sulfamethoxazole | 27/29 (93.1) |
Ampicillin | 6/25 (24.0) |
Ciprofloxacin | 0/22 |
Ceftriaxone |
0/13 |
Treatment | |
Received any treatment | 48/54 (88.9) |
Treated with antimicrobials | 43/53 (81.1) |
Antimicrobial treatment¶ | |
Ciprofloxacin | 19 (45.2) |
Metronidazole | 12 (28.6) |
Ceftriaxone | 5 (11.9) |
Levofloxacin | 5 (11.9) |
Trimethoprim/sulfamethoxazole | 4 (9.5) |
Azithromycin | 4 (9.5) |
Ampicillin | 3 (7.1) |
Amoxicillin | 2 (4.8) |
Other or unknown |
3 (7.1) |
Median interval from diarrhea onset to start of antimicrobial treatment, d (IQR) | 3 (1–5)# |
Treated with intravenous fluids | 23/46 (50.0) |
Received other treatment** | 17/54 (31.5) |
*Values are no. patients/no. with information available (%) excepted as indicated. IQR, interquartile range.
†Based on self-reported data; 19 (52.8%) of 36 patients had documented temperature of ≥38°C.
‡n = 39; includes 6 patients in cluster 2 still symptomatic at time of interview. Illness duration range 5–12 d.
§n = 11.
¶n = 42. Because 10 case-patients were treated with >1 antimicrobial drug, total is >100%.
#n = 35.
**Antiemetics, pain medication, nonprescription antidiarrheal medication.
Page created: March 15, 2016
Page updated: March 15, 2016
Page reviewed: March 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.